JPWO2021163170A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021163170A5 JPWO2021163170A5 JP2022548596A JP2022548596A JPWO2021163170A5 JP WO2021163170 A5 JPWO2021163170 A5 JP WO2021163170A5 JP 2022548596 A JP2022548596 A JP 2022548596A JP 2022548596 A JP2022548596 A JP 2022548596A JP WO2021163170 A5 JPWO2021163170 A5 JP WO2021163170A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- seq
- binding fragment
- acvr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims 41
- 239000000427 antigen Substances 0.000 claims 39
- 108091007433 antigens Proteins 0.000 claims 39
- 102000036639 antigens Human genes 0.000 claims 39
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 claims 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims 29
- 102100034111 Activin receptor type-1 Human genes 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 102000054953 human ACVR1 Human genes 0.000 claims 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 9
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims 6
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims 6
- 238000003556 assay Methods 0.000 claims 6
- 229940112869 bone morphogenetic protein Drugs 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 101100490443 Mus musculus Acvr1 gene Proteins 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 108700028369 Alleles Proteins 0.000 claims 3
- 241000699666 Mus <mouse, genus> Species 0.000 claims 3
- 241000699670 Mus sp. Species 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000011664 signaling Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000034970 Heterotopic Ossification Diseases 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 238000004166 bioassay Methods 0.000 claims 2
- 230000020411 cell activation Effects 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000003702 retinoic acid receptors Human genes 0.000 claims 2
- 108090000064 retinoic acid receptors Proteins 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- 206010049811 Extraskeletal ossification Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 claims 1
- 101000701405 Homo sapiens Serine/threonine-protein kinase 36 Proteins 0.000 claims 1
- 239000000488 activin Substances 0.000 claims 1
- 108010023082 activin A Proteins 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000018511 hepcidin Human genes 0.000 claims 1
- 108060003558 hepcidin Proteins 0.000 claims 1
- 229940066919 hepcidin Drugs 0.000 claims 1
- 230000007941 heterotopic ossification Effects 0.000 claims 1
- 102000046107 human BMP7 Human genes 0.000 claims 1
- 102000053342 human STK36 Human genes 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 229940035363 muscle relaxants Drugs 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 102220077545 rs797045135 Human genes 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062975047P | 2020-02-11 | 2020-02-11 | |
| US62/975,047 | 2020-02-11 | ||
| US202063030131P | 2020-05-26 | 2020-05-26 | |
| US63/030,131 | 2020-05-26 | ||
| PCT/US2021/017427 WO2021163170A1 (fr) | 2020-02-11 | 2021-02-10 | Anticorps anti-acvr1 et leurs utilisations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023519100A JP2023519100A (ja) | 2023-05-10 |
| JPWO2021163170A5 true JPWO2021163170A5 (fr) | 2024-02-22 |
Family
ID=74860418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548596A Pending JP2023519100A (ja) | 2020-02-11 | 2021-02-10 | 抗ａｃｖｒ１抗体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11945872B2 (fr) |
| EP (1) | EP4103617A1 (fr) |
| JP (1) | JP2023519100A (fr) |
| KR (1) | KR20220140802A (fr) |
| CN (1) | CN115362175A (fr) |
| AU (1) | AU2021218675A1 (fr) |
| CA (1) | CA3167441A1 (fr) |
| IL (1) | IL295419A (fr) |
| MX (1) | MX2022009769A (fr) |
| WO (1) | WO2021163170A1 (fr) |
| ZA (1) | ZA202208222B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118176018A (zh) * | 2021-09-03 | 2024-06-11 | 来凯医药科技(上海)有限公司 | 抗acvr2a抗体及其用途 |
| WO2024092133A1 (fr) | 2022-10-27 | 2024-05-02 | Regeneron Pharmaceuticals, Inc. | Anticorps anti-acvr1 et leur utilisation dans le traitement de l'ossification hétérotopique résultant d'un traumatisme |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| WO2005103081A2 (fr) | 2004-04-20 | 2005-11-03 | Genmab A/S | Anticorps monoclonaux humains diriges contre cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| US8859752B2 (en) | 2006-04-18 | 2014-10-14 | The Trustees Of The University Of Pennsylvania | SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP) |
| WO2007123896A2 (fr) | 2006-04-18 | 2007-11-01 | The Trustees Of The University Of Pennsylvania | Acvr1 mutant pour diagnostic et traitement de la fibrodysplasie ossifiante progressive (fop) |
| MX2008014804A (es) | 2006-06-02 | 2009-01-27 | Regeneron Pharma | Anticuerpos de afinidad elevada a receptor de il-6 humano. |
| MX2009008706A (es) | 2007-02-21 | 2009-09-14 | Univ Massachusetts | Anticuerpos humanos contra el virus de la hepatitis c (hcv) y usos de los mismos. |
| CN102471378B (zh) | 2009-06-26 | 2014-04-02 | 瑞泽恩制药公司 | 容易地分离的具有天然免疫球蛋白形式的双特异性抗体 |
| SI3095871T1 (sl) | 2010-02-08 | 2019-06-28 | Regeneron Pharmaceuticals, Inc. | Miš z navadno lahko verigo |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| BR112017015661A2 (pt) | 2015-01-30 | 2018-03-20 | Saitama Medical University | anticorpo anti-alk2 |
| CA3093205A1 (fr) | 2018-03-05 | 2019-09-12 | Saitama Medical University | Composition pharmaceutique pour le traitement ou la prevention de l'ossification heterotopique |
| CN113366019A (zh) | 2018-10-23 | 2021-09-07 | 科乐斯疗法公司 | Alk2抗体及其使用方法 |
| WO2020118011A1 (fr) | 2018-12-06 | 2020-06-11 | Alexion Pharmaceuticals, Inc. | Anticorps anti-alk2 et leurs utilisations |
| JPWO2021020282A1 (fr) | 2019-07-26 | 2021-02-04 |
-
2021
- 2021-02-10 JP JP2022548596A patent/JP2023519100A/ja active Pending
- 2021-02-10 MX MX2022009769A patent/MX2022009769A/es unknown
- 2021-02-10 US US17/172,856 patent/US11945872B2/en active Active
- 2021-02-10 WO PCT/US2021/017427 patent/WO2021163170A1/fr unknown
- 2021-02-10 CA CA3167441A patent/CA3167441A1/fr active Pending
- 2021-02-10 EP EP21710676.4A patent/EP4103617A1/fr active Pending
- 2021-02-10 AU AU2021218675A patent/AU2021218675A1/en active Pending
- 2021-02-10 KR KR1020227031475A patent/KR20220140802A/ko unknown
- 2021-02-10 IL IL295419A patent/IL295419A/en unknown
- 2021-02-10 CN CN202180027355.8A patent/CN115362175A/zh active Pending
-
2022
- 2022-07-22 ZA ZA2022/08222A patent/ZA202208222B/en unknown
-
2024
- 2024-02-22 US US18/584,551 patent/US20240190974A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2904644C (fr) | Anticorps humains se liant a grem1 | |
| CN112969719B (zh) | 双功能融合蛋白及其医药用途 | |
| KR20110040886A (ko) | 프로스타글란딘 ｅ2 결합 단백질 및 이의 용도 | |
| TW201204831A (en) | Dual variable domain immunoglobulins and uses thereof | |
| KR20120089659A (ko) | 치료용 ｄｌｌ4 결합 단백질 | |
| CN112585165A (zh) | 优化的抗tl1a抗体 | |
| JP2010501164A5 (fr) | ||
| JP2005528914A5 (fr) | ||
| CN112243443B (zh) | 抗trop-2抗体、其抗原结合片段及其医药用途 | |
| KR20150136031A (ko) | 인간화 또는 친화도 성숙된 항 앤지오포이에틴-2 항체 및 그의 용도 | |
| US20230048260A1 (en) | Therapeutic anti-cd40 ligand antibodies | |
| JP2020515277A5 (fr) | ||
| CN111375059A (zh) | 一种抗gitr抗体药物组合物及其用途 | |
| WO2021259335A1 (fr) | Anticorps monoclonaux humains dirigés contre tigit pour des maladies liées à l'immunité | |
| CN113227148B (zh) | 抗gpc3抗体、其抗原结合片段及其医药用途 | |
| WO2021160116A1 (fr) | Anticorps anti-fcrn, fragment de liaison à l'antigène de celui-ci et utilisation pharmaceutique de ceux-ci | |
| CN111683965A (zh) | 用于治疗骨折或骨缺损的gremlin-1抑制剂 | |
| CN115298216A (zh) | 抗体或其抗原结合片段、其制备方法及医药用途 | |
| JPWO2021163170A5 (fr) | ||
| JPWO2020086406A5 (fr) | ||
| JP2019518473A5 (fr) | ||
| WO2024061224A1 (fr) | Anticorps anti-her2 et leur utilisation | |
| JP2011050355A (ja) | トランスポーターに対する抗体およびその用途 | |
| WO2024140031A1 (fr) | Anticorps ciblant cd112r ou fragment de liaison à l'antigène de celui-ci et son utilisation | |
| TW202333788A (zh) | 一種抗ｔｎｆｒ２抗體藥物組合物 |